Total Payments
$807,524
2024 Payments
$61,727
Companies
38
Transactions
904
Medicare Patients
308
Medicare Billing
$61,897
Payment Breakdown by Category
Other$613,712 (76.0%)
Travel$104,006 (12.9%)
Consulting$71,164 (8.8%)
Food & Beverage$17,964 (2.2%)
Education$408.12 (0.1%)
Research$270.72 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $565,605 | 174 | 70.0% |
| Travel and Lodging | $104,006 | 310 | 12.9% |
| Consulting Fee | $71,164 | 46 | 8.8% |
| Honoraria | $37,877 | 16 | 4.7% |
| Food and Beverage | $17,964 | 322 | 2.2% |
| Grant | $10,230 | 1 | 1.3% |
| Education | $408.12 | 34 | 0.1% |
| Unspecified | $270.72 | 1 | 0.0% |
Payments by Type
General
$807,254
903 transactions
Research
$270.72
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $218,134 | 232 | $0 (2024) |
| Seagen Inc. | $135,910 | 112 | $0 (2023) |
| Gilead Sciences, Inc. | $95,975 | 72 | $0 (2021) |
| Seattle Genetics, Inc. | $89,758 | 103 | $0 (2019) |
| Kite Pharma, Inc. | $67,820 | 64 | $0 (2024) |
| Lilly USA, LLC | $63,987 | 58 | $0 (2024) |
| PFIZER INC. | $35,644 | 27 | $0 (2024) |
| Acrotech Biopharma Inc. | $27,557 | 30 | $0 (2023) |
| Kyowa Kirin, Inc. | $18,094 | 31 | $0 (2024) |
| Aurobindo Pharma USA, Inc. | $14,060 | 39 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,727 | 73 | PFIZER INC. ($31,891) |
| 2023 | $148,528 | 143 | Daiichi Sankyo Inc. ($40,379) |
| 2022 | $103,387 | 98 | Seagen Inc. ($36,735) |
| 2021 | $83,865 | 70 | Seagen Inc. ($40,835) |
| 2020 | $85,847 | 108 | Daiichi Sankyo Inc. ($31,454) |
| 2019 | $87,429 | 122 | Gilead Sciences, Inc. ($26,654) |
| 2018 | $135,692 | 137 | Seattle Genetics, Inc. ($41,249) |
| 2017 | $101,050 | 153 | Daiichi Sankyo Inc. ($33,043) |
All Payment Transactions
904 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $54.57 | General |
| Category: HEMATOLOGY | ||||||
| 12/03/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $719.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $109.55 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $96.88 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $79.50 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $38.22 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $5.44 | General |
| Category: Oncology | ||||||
| 11/15/2024 | PFIZER INC. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $87.76 | General |
| Category: CELLT | ||||||
| 09/03/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $109.12 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Travel and Lodging | Cash or cash equivalent | $96.88 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $32.68 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $27.22 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $22.59 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Incyte Corporation | — | Education | Cash or cash equivalent | $74.99 | General |
| 07/26/2024 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $87.23 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 07/15/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 07/11/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $122.25 | General |
| Category: Oncology | ||||||
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Oncology | ||||||
| 06/27/2024 | PFIZER INC. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: Oncology | ||||||
| 06/27/2024 | PFIZER INC. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $1,564.08 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LAB-BASED RESPONSE ASSESSMENT ALGORITHM RECAPITULATES INVESTIGATOR S RESPONSE ASSESSMENT IN THE PHASE 3 BELLINI TRIAL | F. Hoffmann-La Roche AG | $270.72 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 73 | 146 | $66,280 | $13,232 |
| 2022 | 3 | 75 | 141 | $74,790 | $14,342 |
| 2021 | 2 | 83 | 144 | $72,410 | $17,249 |
| 2020 | 2 | 77 | 143 | $71,090 | $17,075 |
Total Patients
308
Total Services
574
Medicare Billing
$61,897
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 72 | $38,160 | $7,457 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 74 | $28,120 | $5,775 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 51 | 115 | $60,950 | $11,439 | 18.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $8,140 | $1,642 | 20.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 15 | $5,700 | $1,262 | 22.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 60 | 113 | $54,990 | $12,328 | 22.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 31 | $17,420 | $4,921 | 28.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 57 | 120 | $61,200 | $14,838 | 24.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 20 | 23 | $9,890 | $2,236 | 22.6% |
About Dr. Ahmed Sawas, M.D
Dr. Ahmed Sawas, M.D is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2008. The National Provider Identifier (NPI) number assigned to this provider is 1134379043.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ahmed Sawas, M.D has received a total of $807,524 in payments from pharmaceutical and medical device companies, with $61,727 received in 2024. These payments were reported across 904 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($565,605).
As a Medicare-enrolled provider, Sawas has provided services to 308 Medicare beneficiaries, totaling 574 services with total Medicare billing of $61,897. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location New York, NY
- Active Since 09/27/2008
- Last Updated 05/18/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1134379043
Products in Payments
- ADCETRIS (Biological) $239,971
- INJECTAFER (Drug) $218,134
- Zydelig (Drug) $91,356
- Yescarta (Drug) $37,990
- BELEODAQ (Drug) $27,557
- JAYPIRCA (Drug) $19,063
- SGN35 (Biological) $16,018
- POTELIGEO (Drug) $12,382
- Beleodaq (Drug) $10,246
- Zevalin (Drug) $9,277
- Imbruvica (Drug) $6,617
- SANCUSO (Drug) $5,333
- MONOFERRIC (Drug) $4,634
- IMBRUVICA (Drug) $3,826
- DepoCyt (Drug) $3,617
- Monoferric (Drug) $1,408
- COPIKTRA (Drug) $495.03
- LIBTAYO (Biological) $350.00
- Folotyn (Drug) $217.99
- Poteligeo (Drug) $217.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205
Dr. Ajai Chari, M.d, M.D
Hematology & Oncology — Payments: $536,082
Hematology & Oncology $536,082